Reboxetine prevents the tranylcypromine-induced
increase in tyramine levels in rat heart

by
Dostert P, Castelli MG, Cicioni P, Strolin Benedetti M
Farmitalia Carlo Erba,
Research and Development,
Erbamont Group, Milan, Italy.
J Neural Transm Suppl 1994; 41:149-53


ABSTRACT

This study aimed to examine whether the increase in heart radioactivity levels after intravenous injection of 14C-tyramine to rats pretreated with the irreversible MAO inhibitor tranylcypromine could be antagonized by reboxetine, a potent and selective noradrenaline uptake blocker. Reboxetine was found totally to abolish the effect of tranylcypromine. Heart radioactivity levels after reboxetine and tranylcypromine were very similar to those found when tyramine was injected after reboxetine only. These results suggest that reboxetine might be advantageously combined with tranylcypromine, or any MAO inhibitor, in depressed patients unresponsive of either treatment given alone.


SSRIs
MAOIs
Serotonin
Reboxetine
Venlafaxine
Noradrenaline
Tranylcypromine
Reboxetine: product info
Serotonin reuptake inhibition
Dopamine reuptake inhibition
Noradrenergic antidepressants
Noradrenaline reuptake inhibition


Refs
and further reading

HOME
HedWeb
Nootropics
Cocaine.org
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family